|
|
|
Volumn 10, Issue 4, 2012, Pages 255-256
|
|
Advances in drug development: New approaches to thyroid cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
B RAF KINASE;
CABOZANTINIB;
CALCITONIN;
CEDIRANIB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
INLYTA;
K RAS PROTEIN;
LENALIDOMIDE;
MOTESANIB;
PAZOPANIB;
PHOSPHATIDYLINOSITOL 3 KINASE;
PROTEIN P53;
PROTEIN RET;
PROTEIN TYROSINE KINASE INHIBITOR;
RADIOACTIVE IODINE;
SORAFENIB;
SUNITINIB;
UNCLASSIFIED DRUG;
VANDETANIB;
VASCULOTROPIN RECEPTOR;
VEMURAFENIB;
ANTINEOPLASTIC AGENT;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
RET PROTEIN, HUMAN;
ARTICLE;
EXTERNAL BEAM RADIOTHERAPY;
GENE MUTATION;
HUMAN;
ONCOCYTOMA;
THYROID CANCER;
THYROID FOLLICULAR CARCINOMA;
THYROID PAPILLARY CARCINOMA;
THYROID PARAFOLLICULAR CELL;
DRUG ANTAGONISM;
DRUG EFFECT;
GENETICS;
INTERVIEW;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
MUTATION;
PATHOLOGY;
THYROID GLAND;
THYROID TUMOR;
ANTINEOPLASTIC AGENTS;
HUMANS;
MOLECULAR TARGETED THERAPY;
MUTATION;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
PROTO-ONCOGENE PROTEINS B-RAF;
PROTO-ONCOGENE PROTEINS C-RET;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
THYROID GLAND;
THYROID NEOPLASMS;
|
|
EID: 84859639414
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (3)
|
